Drug-Drug Interactions with Kinase Inhibitors

GI CONNECT has been involved with a comprehensive resource available on ESMO OncologyPRO, providing information on the management of kinase inhibitor-associated drug-drug interactions

Drug-Drug Interactions with Kinase Inhibitors

This material has been developed as a comprehensive resource providing information and guidance on the management of kinase inhibitor-associated drug-drug interactions.

At the time of writing (2015), there was a lack of guidelines for managing drug-drug interactions with kinase inhibitors.

Information included in this material is compiled from review of the medical literature and expert guidance from Prof. Hans Gelderblom and Prof. Claus-Henning Koehne (clinical oncologists), Dr. Roelof W F van Leeuwen (clinical pharmacist) and Dr. Vincent Launay-Vacher (clinical pharmacologist).

The resource aims to:

• Understand the clinically relevant drug-drug interactions with kinase inhibitors
• Explore the type and mechanism of the interaction: altered bioavailability due to altered stomach pH, metabolism by cytochrome P450 isoenzymes, and prolongation of the QTc interval
• Provide specific recommendations to guide physicians and clinical pharmacists in the management of drug-drug interactions during treatment with kinase inhibitors in daily clinical practice

COR2ED have donated this content to ESMO to ensure that the practical guide reflects today's best clinical practice.